ENT Disorder Treatment Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-02-11　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 36.53 Bn
2033 年預估規模: USD 57.30 Bn
年複合成長率 CAGR: 6.6%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

ENT Disorder Treatment Market, By Treatment Type (By Devices (Hearing Aid Devices, Voice Prostheses, Nasal Splints, Hearing Implants, Others)), By Drugs (Antibiotics, Antihistamines, Steroids, Anti-inflammatory Drugs, Others), By Organ Type (Ears, Nose, Throat), By End User (Hospital, Clinics, Ambulatory Surgical Centers, Home Care Settings, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

ENT also known as otolaryngology is a stream of medical science that deals with disorders associated with ear, nose, and throat. Diseases related to ears, throat, and nose significantly affect the quality of life and could lead to surgeries in few cases such as chronic tonsillitis, ear infections, and severe sinusitis problems as well as cancers of the throat or larynx, and others. In order to treat these disorders, ENT treatment is required. These diseases can either be treated with the help of devices or drugs, however, surgeries are recommended to patients with severe cases. Surgical procedures are required in few cases such as throat cancer as recommended by otolaryngologist, however, an oncologist performs the tumor removal procedures, which is either followed by a radiation or chemotherapy, depending on the severity. Market Dynamics Key players are focusing on inorganic growth strategies such as agreement and acquisitions for enhancement of research department as well as commercialization of products in terms of sales and marketing. For instance, in July 2017, Entellus Medical announced a definitive agreement to acquire Spirox, Inc. a privately held ENT medical technology that develops, manufactures and markets absorbable nasal implants and other medical devices. Moreover, in August 2021, Medtronic plc., the global leader in medical technology signed agreement with Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic acquired all shares of Intersect ENT for USD28.25 per share in an all-cash transaction implying an enterprise value of approximately USD1.1 billion. The boards of directors of both companies have unanimously approved the transaction. Medtronic's acquisition of Intersect ENT expands the company's portfolio of products used during ear, nose, and throat procedures. The complementary product lines and Medtronic's efforts to have a positive impact for patients who suffer from chronic rhinosinusitis (CRS). Intersect ENT's PROPEL® and SINUVA® sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing. By combining these products with Medtronic's navigation, powered instruments, and existing tissue health products, the company intends to offer a broader suite of solutions to assist surgeons treating CRS patients. Key features of the study • This report provides an in-depth analysis of the global ENT disorder treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global ENT disorder treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddys Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc., and Zounds Inc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global ENT disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ENT disorder treatment market Market Segmentation • Treatment Type Insights (Revenue, USD Bn, 2026 - 2033) o By Devices  Hearing Aid Devices  Voice Prostheses  Nasal Splints  Hearing Implants  Others o By Drugs  Antibiotics  Antihistamines  Steroids  Anti-inflammatory Drugs  Others • Organ Type Insights (Revenue, USD Bn, 2026 - 2033) o Ears o Nose o Throat • End User Insights (Revenue, USD Bn, 2026 - 2033) o Hospital o Clinics o Ambulatory Surgical Centers o Home Care Settings o Others • Regional Insights (Revenue, USD Bn, 2026 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC  Israel  Rest of Middle East o Africa  North Africa  Central Africa  South Africa • Key Players Insights o Sanofi o AstraZeneca Plc o Novartis AG o Pfizer, Inc. o Mylan N.V. o Teva Pharmceutical Industries Ltd. o GlaxoSmithKline Plc o Otonomy, Inc. o Merck & Co., Inc. o Dr. Reddy’s Laboratories Ltd. o Allergen Plc o Cochlear Ltd. o Sonova Holdings AG. o Siemens Healthineers o Starkey Laboratories, Inc. o William Demant Holdings, A/S o Widex A/S o GN Re/Sound A/S o Sonic Innovations. Inc. o Panasonic Corporation o Beltone o Rexton Inc. o Avada Hearing Care o Miracle-Ear., Inc. o MED-EL GmBH o Nuear Hearing Aids, Inc. o AudioSync, Inc. o Bernafon o American Hearing Systems, Inc. o Unitron Hearing, Inc. o Zounds, Inc.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Overview o Report Description  Market Definition and Scope o Executive Summary  Global ENT Disorder Treatment Market, By Treatment Type  Global ENT Disorder Treatment Market, By Organ Type  Global ENT Disorder Treatment Market, By End User  Global ENT Disorder Treatment Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trend 4. Global ENT Disorder Treatment Market, By Treatment Type, 2020-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o By Devices  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)  Segment Trends o Hearing Aid Devices o Voice Prostheses o Nasal Splints o Hearing Implants o Others o By Drugs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)  Segment Trends o Antibiotics o Antihistamines o Steroids o Anti-inflammatory Drugs o Others 5. Global ENT Disorder Treatment Market, By Organ Type, 2020-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Ears  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Nose  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Throat  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) 6. Global ENT Disorder Treatment Market, By End User, 2020-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hospital  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Clinics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Ambulatory Surgical Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Home Care Settings  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn) 7. Global ENT Disorder Treatment Market, By Region, 2020 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 8. Competitive Landscape o Sanofi  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AstraZeneca Plc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Pfizer, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Mylan N.V.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Teva Pharmceutical Industries Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o GlaxoSmithKline Plc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Otonomy, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Merck & Co., Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Dr. Reddy’s Laboratories Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Allergen Plc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Cochlear Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sonova Holdings AG.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Siemens Healthineers  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Starkey Laboratories, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o William Demant Holdings, A/S  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Widex A/S  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o GN Re/Sound A/S  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sonic Innovations. Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Panasonic Corporation  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Beltone  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Rexton Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Avada Hearing Care  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Miracle-Ear., Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o MED-EL GmBH  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Nuear Hearing Aids, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AudioSync, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bernafon  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o American Hearing Systems, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Unitron Hearing, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Zounds, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 9. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 10. References and Research Methodology o References o Research Methodology o About us

提及公司

SanofiAstraZeneca PlcNovartis AGPfizer, Inc.Mylan N.V.Teva Pharmceutical Industries Ltd.GlaxoSmithKline PlcOtonomy, Inc.Merck & Co., Inc.Dr. Reddy’s Laboratories Ltd.Allergen PlcCochlear Ltd.Sonova Holdings AG.Siemens HealthineersStarkey Laboratories, Inc.William Demant Holdings, A/SWidex A/SGN Re/Sound A/SSonic Innovations. Inc.Panasonic CorporationBeltoneRexton Inc.Avada Hearing CareMiracle-Ear., Inc.MED-EL GmBHNuear Hearing Aids, Inc.AudioSync, Inc.BernafonAmerican Hearing Systems, Inc.Unitron Hearing, Inc.

同分類最新報告（醫療器材）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們